Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. E18, 1998, Pages

  Turpie, Alexander G G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HHSC General Campus ^*  (Canada)

Author keywords

Enoxaparin; Low molecular weight heparin; Thrombolysis in myocardial infarction 11A program; Thrombolysis in myocardial infarction 11B program; Unstable angina

Indexed keywords

ENOXAPARIN; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE DISEASE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MALE; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; CORONARY DISEASE; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE;

EID: 0032135009     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia: WB Saunders Co, 1992:17-39.
2. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation 1994;89:1449-68.
3. Lewis HD Jr, Davi, JW, Archibald DO, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1933;309:396-403.
4. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian Multicenter trial. N Engl J Med 1985;313:1369-75.
5. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
6. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
7. Weitz J, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993;122:364-73.
8. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end-points analysis from the ATAC trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994;89:81-8.
9. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
10. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
11. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984;35:613-25.
12. Turpie AGO. New therapeutic opportunities for heparins: What does low molecular weight heparin offer? J Thromb Thrombolysis 1996;3:145-9.
13. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
14. Wallentin L, Ohlsson J, Swahn E, for the Fragmin during instability in coronary artery disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
15. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular weight-heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation 1997;96:61-8.
16. Cohen M, Demers C, Gurfinkel MD, et al. Low-molecular-weight heparin versus unfractionated heparin for unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1997;337:447-52.
17. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.